abrdn Life Sciences Investors Q2 2026 Commentary
· seekingalpha.com
The equity portion of the Fund rose (gross of fees) and outperformed its benchmark, the NASDAQ Biotechnology Index. Read more here.
Benjamas Deekam/iStock via Getty Images
Fund performance
The equity portion of the Fund rose (gross of fees) and outperformed its benchmark, the NASDAQ Biotec...